Women are more prone to certain diseases, mostly related to menstrual disorders, depression, osteoporosis, obesity, and autoimmune diseases. Women's major health issues are related to the reproductive system that includes infertility, polycystic ovarian syndrome, menopause, and cancers such as breast cancer, cervical cancer, and urological disorders. Chronic diseases, such as heart disease, cancer and stroke, cause more death, illness and disability in the United States than any other cause. As indicated by, Centers for Disease Control and Prevention (CDC) each year, more than 1.7 million Americans die from a chronic disease, accounting for seven out of every 10 deaths. While chronic disease is the leading cause of death for men and women alike, women face unique health challenges. Thirty-eight percent of women suffer from one or more chronic diseases, compared to 30 percent of men.
Global women’s health therapeutics market has been growing at a phenomenal pace in the past few years due to increasing awareness about various health-related disorders among women, rising incidence of various chronic and lifestyle disorders, high adoption of diagnostics imaging procedure and high prevalence of chronic diseases such as HIV, Urinary incontinence, Breast cancer in women across the globe. For Instance, As indicated by Phoenix Physical Therapy, Urinary Incontinence affects 200 million people worldwide of the 25 million adult Americans suffering from some form of urinary incontinence, 75-80% of those are women. In addition, rising number of menopausal conditions amongst women coupled with the changing lifestyles and poor dietary habits and growing investment by key market players to fulfil demand in areas of infection, cancer, and pregnancy-related complications are also expected to boost the women health therapeutics market.
The global Women’s Health Therapeutics Market is segmented by Treatment Type, Disease Indication and Geography.
Based on treatment type, the market is categorised into Hormonal Treatment and Non-Hormonal Treatment. Hormonal treatment segment is further categorised into Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, and others. Further on, Non-Hormonal Treatment segment comprises Cancer Targeted Therapy Drugs, Antibiotics, Bisphosphonates and others.
The market for the Hormonal treatment has recorded positive inclining growth due to growing demand for postmenopausal hormone therapy. The non-hormonal treatment has comparatively least efficacy to produce optimum results. However the risk of breast cancer associated with the hormonal products has boosted the demand for non-hormonal pharmaceutical products.
Based on disease indication, the Global Women’s Health Market is bifurcated into Cancer, Hypothyroidism, Post-Menopausal Syndrome, Osteoporosis, Contraceptive, Uterine Fibroid, Urinary Tract Infection and others. The Cancer segment comprises of Breast Cancer, Cervical Cancer and Ovarian Cancer. The demand for breast cancer therapeutics is growing due to the high prevalence of breast cancer across the globe. Breast cancer is the most frequent cancer among women. As per World Health Organisation Data, breast cancer is impacting 2.1 million women each year. In 2018, it is estimated that 627,000 women died from breast cancer. The breast cancer mortality rate is approximately 15% of all cancer deaths among women. While breast cancer rates are higher among women in more developed regions, rates are increasing in nearly every region globally.
The Women’s Health Therapeutics Market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global Women’s Health Therapeutics Market in 2018. The large share of the market is attributed to the factors such as the rising incidence of breast cancer coupled with the easy accessibility and high adoption of advanced diagnostic technologies, significant per capita annual healthcare expenditure in the US and Canada, and the rapidly increasing geriatric population in the region. Further, growing incidence of lifestyle related health disorders, rising focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and increasing demand for fertility testing monitors are also the major factors attributed to the growth of the market.
However, the Asia-Pacific market is expected to grow at the highest CAGR during the forecast period. A number of factors, such as the growing patient populace, improving healthcare infrastructure, rising government spending on breast cancer research studies, growing healthcare expenditure and implementation of several initiatives to create awareness about the early detection of breast cancer are expected to drive the market in the Asia-Pacific region during the forecast period.
Some of the key players operating in the global Women’s Health Therapeutics Market are Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi, Allergan Plc, Bayer AG, GlaxoSmithKline plc, and Johnson & Johnson among others.
The global Women’s Health Therapeutics Market is segmented by Treatment Type, Disease Indication and Geography.
Based on treatment type, the market is categorised into Hormonal Treatment and Non-Hormonal Treatment. Hormonal treatment segment is further categorised into Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, and others. Further on, Non-Hormonal Treatment segment comprises Cancer Targeted Therapy Drugs, Antibiotics, Bisphosphonates and others.
Based on disease indication, the Global Women’s Health Market is bifurcated into Cancer, Hypothyroidism, Post-Menopausal Syndrome, Osteoporosis, Contraceptive, Uterine Fibroid, Urinary Tract Infection and others. The Cancer segment comprises of Breast Cancer, Cervical Cancer and Ovarian Cancer.
Geographically, the market is studied for the key countries of North America, Europe, Asia-Pacific and Rest of the World. The major players involved in this market are Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi, Allergan Plc, GlaxoSmithKline plc and Lupin Pharmaceuticals, Inc. among others.
Why to buy this report: